FAS
- Aliases
-
- ALPS1A
- APO-1
- APO-1 cell surface antigen
- APT1
- Apo-1 antigen
- Apoptosis-mediating surface antigen FAS
- CD95
- CD95 antigen
- Delta Fas/APO-1/CD95
- FAS
- FAS (Ab1)
- FAS (Ab2)
- FAS 827dupA
- FAS1
- FASLG receptor
- FASTM
- Fas (TNF receptor superfamily, member 6)
- Fas AMA
- TNFRSF6
- apoptosis antigen 1
- apoptosis-mediating surface antigen FAS
- tumor necrosis factor receptor superfamily member 6
- tumor necrosis factor receptor superfamily, member 6
- Description
- FAS is a member of the TNF-receptor superfamily. The FAS protein is a receptor for TNFSF6/FASLG and has been shown to play a central role in the physiological regulation of programmed cell death, and has been implicated in the pathogenesis of various malignancies and diseases of the immune system. Several alternatively spliced transcript variants have been described, some of which are candidates for nonsense-mediated mRNA decay (NMD). The isoforms lacking the transmembrane domain may negatively regulate the apoptosis mediated by the full length isoform.
Attributes
- QA State
- Curated
- Type
- Protein
- HGNC Name
- FAS
- Certifications
-
- None
- QA State for Breast
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Ovary
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.